TScan Therapeutics Statistics
Total Valuation
TCRX has a market cap or net worth of $95.64 million. The enterprise value is -$52.22 million.
Important Dates
The last earnings date was Tuesday, May 6, 2025, before market open.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRX has 56.59 million shares outstanding. The number of shares has increased by 18.13% in one year.
| Current Share Class | 52.31M |
| Shares Outstanding | 56.59M |
| Shares Change (YoY) | +18.13% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.76% |
| Owned by Institutions (%) | 60.58% |
| Float | 40.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.66 |
| Forward PS | 24.24 |
| PB Ratio | 0.48 |
| P/TBV Ratio | 0.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.55, with a Debt / Equity ratio of 0.46.
| Current Ratio | 8.55 |
| Quick Ratio | 8.44 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -41.42 |
Financial Efficiency
Return on equity (ROE) is -78.93% and return on invested capital (ROIC) is -33.45%.
| Return on Equity (ROE) | -78.93% |
| Return on Assets (ROA) | -30.45% |
| Return on Invested Capital (ROIC) | -33.45% |
| Return on Capital Employed (ROCE) | -46.12% |
| Revenue Per Employee | $22,672 |
| Profits Per Employee | -$674,277 |
| Employee Count | 195 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.36% in the last 52 weeks. The beta is 0.97, so TCRX's price volatility has been similar to the market average.
| Beta (5Y) | 0.97 |
| 52-Week Price Change | -79.36% |
| 50-Day Moving Average | 1.43 |
| 200-Day Moving Average | 3.19 |
| Relative Strength Index (RSI) | 61.13 |
| Average Volume (20 Days) | 836,661 |
Short Selling Information
The latest short interest is 2.30 million, so 4.07% of the outstanding shares have been sold short.
| Short Interest | 2.30M |
| Short Previous Month | 1.79M |
| Short % of Shares Out | 4.07% |
| Short % of Float | 5.66% |
| Short Ratio (days to cover) | 6.06 |
Income Statement
In the last 12 months, TCRX had revenue of $4.42 million and -$131.48 million in losses. Loss per share was -$2.32.
| Revenue | 4.42M |
| Gross Profit | -5.36M |
| Operating Income | -139.70M |
| Pretax Income | -96.80M |
| Net Income | -131.48M |
| EBITDA | -136.17M |
| EBIT | -139.70M |
| Loss Per Share | -$2.32 |
Full Income StatementBalance Sheet
The company has $251.69 million in cash and $97.04 million in debt, giving a net cash position of $154.65 million or $2.73 per share.
| Cash & Cash Equivalents | 251.69M |
| Total Debt | 97.04M |
| Net Cash | 154.65M |
| Net Cash Per Share | $2.73 |
| Equity (Book Value) | 210.20M |
| Book Value Per Share | 3.71 |
| Working Capital | 225.02M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$119.14 million and capital expenditures -$4.65 million, giving a free cash flow of -$123.79 million.
| Operating Cash Flow | -119.14M |
| Capital Expenditures | -4.65M |
| Free Cash Flow | -123.79M |
| FCF Per Share | -$2.19 |
Full Cash Flow StatementMargins
| Gross Margin | -121.15% |
| Operating Margin | -3,159.87% |
| Pretax Margin | -2,974.08% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.13% |
| Shareholder Yield | -18.13% |
| Earnings Yield | -128.37% |
| FCF Yield | -120.86% |
Analyst Forecast
The average price target for TCRX is $9.50, which is 462.13% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.50 |
| Price Target Difference | 462.13% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 114.25% |
| EPS Growth Forecast (5Y) | -24.27% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TCRX has an Altman Z-Score of -0.94 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.94 |
| Piotroski F-Score | 2 |